Journal of Cancer Therapeutics & Research

Journal of Cancer Therapeutics & Research

ISSN 2049-7962
Review

An update on current management of advanced renal cell cancer, biomarkers, and future directions

Wanqing Iris Zhi* and Jenny J. Kim

*Corresponding author: Wanqing Iris Zhi wzhi1@jhmi.edu

The Sidney Kimmel Cancer Comprehensive Center, Johns Hopkins Hospital, Baltimore, USA.

Author Affiliations

The Sidney Kimmel Cancer Comprehensive Center, Johns Hopkins Hospital, Baltimore, USA.

Abstract

In the past decade, metastatic renal cell carcinoma (mRCC) treatment underwent significant advancement that resulted in an unprecedented improvement in the prognosis of this disease. This review will provide an updated review of currently approved treatment options, namely antiangiogenic and immunotherapy, as well as treatment guideline recommended by the National Comprehensive Cancer Network (NCCN). We will summarize studies ongoing in determining prognostic and predictive biomarkers in maximizing therapeutic benefit in the treatment of this disease. Lastly, we will discuss promising agents in clinical testing.

Keywords: Renal cell carcinoma, target therapy, immunotherapy, tyrosine kinase inhibitor, monoclonal antibody, VEGF pathway, mTOR pathway, anti-PD-1 antibody, anti-CTLA-4 antibody, IL-2

ISSN 2049-7962
Volume 3
Abstract Download